tsh biopharmoration Ltd Asset Resilience Ratio
tsh biopharmoration Ltd asset resilience ratio. tsh biopharmoration Ltd (8432) has an Asset Resilience Ratio of 20.36% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See tsh biopharmoration Ltd (8432) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of tsh biopharmoration Ltd (2017–2024)
Asset resilience ratio of tsh biopharmoration Ltd from 2017 to 2024. This chart shows how tsh biopharmoration Ltd's Asset Resilience Ratio has changed over time. Read 8432 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down tsh biopharmoration Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 8432 asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$377.13 Million | 20.36% |
| Total Liquid Assets | NT$377.13 Million | 20.36% |
Asset Resilience Insights
- Good Liquidity Position: tsh biopharmoration Ltd maintains a healthy 20.36% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
tsh biopharmoration Ltd Industry Peers by Asset Resilience Ratio
Compare tsh biopharmoration Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
tsh biopharmoration Ltd Asset Resilience Ratio by Year (2017–2024)
tsh biopharmoration Ltd asset resilience ratio by year from 2017 to 2024. The table below shows the annual Asset Resilience Ratio data for tsh biopharmoration Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 16.77% | NT$309.01 Million ≈ $9.74 Million |
NT$1.84 Billion ≈ $58.04 Million |
+2.81pp |
| 2023-12-31 | 13.97% | NT$195.54 Million ≈ $6.16 Million |
NT$1.40 Billion ≈ $44.10 Million |
-8.81pp |
| 2022-12-31 | 22.78% | NT$326.86 Million ≈ $10.30 Million |
NT$1.44 Billion ≈ $45.21 Million |
-7.28pp |
| 2021-12-31 | 30.06% | NT$351.52 Million ≈ $11.07 Million |
NT$1.17 Billion ≈ $36.84 Million |
+3.30pp |
| 2020-12-31 | 26.76% | NT$328.97 Million ≈ $10.36 Million |
NT$1.23 Billion ≈ $38.73 Million |
-9.51pp |
| 2019-12-31 | 36.27% | NT$458.39 Million ≈ $14.44 Million |
NT$1.26 Billion ≈ $39.82 Million |
-5.76pp |
| 2018-12-31 | 42.03% | NT$512.94 Million ≈ $16.16 Million |
NT$1.22 Billion ≈ $38.45 Million |
+10.83pp |
| 2017-12-31 | 31.20% | NT$399.90 Million ≈ $12.60 Million |
NT$1.28 Billion ≈ $40.38 Million |
-- |
About tsh biopharmoration Ltd
TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan. The company offers prescription medication for cardiovascular, central nervous, gastrointestinal, and others. It also provides MPap, a methylation-specific qPCR technology to detect the methylation status of CDO1 and BHLHE22 genes using cervical scraping; AlphaLiquid Detect, a hybrid capture NGS-based liquid … Read more